The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1NSKBQ     [(2R)-2-hydroxy-3-[(Z)- octadec-9-enoyl]oxy...

Synonyms: CHEMBL117021, LysoPA(18:1), BSPBio_001406, CHEBI:62837, HMDB07855, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of lysophosphatidic acid


High impact information on lysophosphatidic acid


Chemical compound and disease context of lysophosphatidic acid


Biological context of lysophosphatidic acid


Anatomical context of lysophosphatidic acid


Associations of lysophosphatidic acid with other chemical compounds


Gene context of lysophosphatidic acid


Analytical, diagnostic and therapeutic context of lysophosphatidic acid


  1. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Maekawa, M., Ishizaki, T., Boku, S., Watanabe, N., Fujita, A., Iwamatsu, A., Obinata, T., Ohashi, K., Mizuno, K., Narumiya, S. Science (1999) [Pubmed]
  2. Plasma lysophosphatidic acid concentration and ovarian cancer. Baker, D.L., Morrison, P., Miller, B., Riely, C.A., Tolley, B., Westermann, A.M., Bonfrer, J.M., Bais, E., Moolenaar, W.H., Tigyi, G. JAMA (2002) [Pubmed]
  3. Lysophosphatidic acid inhibits cholera toxin-induced secretory diarrhea through CFTR-dependent protein interactions. Li, C., Dandridge, K.S., Di, A., Marrs, K.L., Harris, E.L., Roy, K., Jackson, J.S., Makarova, N.V., Fujiwara, Y., Farrar, P.L., Nelson, D.J., Tigyi, G.J., Naren, A.P. J. Exp. Med. (2005) [Pubmed]
  4. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. Boucharaba, A., Serre, C.M., Grès, S., Saulnier-Blache, J.S., Bordet, J.C., Guglielmi, J., Clézardin, P., Peyruchaud, O. J. Clin. Invest. (2004) [Pubmed]
  5. Platelets and metastasis revisited: a novel fatty link. Gupta, G.P., Massagué, J. J. Clin. Invest. (2004) [Pubmed]
  6. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Agarwal, A.K., Arioglu, E., De Almeida, S., Akkoc, N., Taylor, S.I., Bowcock, A.M., Barnes, R.I., Garg, A. Nat. Genet. (2002) [Pubmed]
  7. The Rho family GTPases RhoA, Rac1, and CDC42Hs regulate transcriptional activation by SRF. Hill, C.S., Wynne, J., Treisman, R. Cell (1995) [Pubmed]
  8. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Inoue, M., Rashid, M.H., Fujita, R., Contos, J.J., Chun, J., Ueda, H. Nat. Med. (2004) [Pubmed]
  9. Endophilin I mediates synaptic vesicle formation by transfer of arachidonate to lysophosphatidic acid. Schmidt, A., Wolde, M., Thiele, C., Fest, W., Kratzin, H., Podtelejnikov, A.V., Witke, W., Huttner, W.B., Söling, H.D. Nature (1999) [Pubmed]
  10. CtBP/BARS induces fission of Golgi membranes by acylating lysophosphatidic acid. Weigert, R., Silletta, M.G., Spanò, S., Turacchio, G., Cericola, C., Colanzi, A., Senatore, S., Mancini, R., Polishchuk, E.V., Salmona, M., Facchiano, F., Burger, K.N., Mironov, A., Luini, A., Corda, D. Nature (1999) [Pubmed]
  11. Lanthanide complexes as fluorescent indicators for neutral sugars and cancer biomarkers. Alptürk, O., Rusin, O., Fakayode, S.O., Wang, W., Escobedo, J.O., Warner, I.M., Crowe, W.E., Král, V., Pruet, J.M., Strongin, R.M. Proc. Natl. Acad. Sci. U.S.A. (2006) [Pubmed]
  12. Dual mechanisms for lysophospholipid induction of proliferation of human breast carcinoma cells. Goetzl, E.J., Dolezalova, H., Kong, Y., Zeng, L. Cancer Res. (1999) [Pubmed]
  13. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Hideshima, T., Chauhan, D., Hayashi, T., Podar, K., Akiyama, M., Mitsiades, C., MItsiades, N., Gong, B., Bonham, L., de Vries, P., Munshi, N., Richardson, P.G., Singer, J.W., Anderson, K.C. Cancer Res. (2003) [Pubmed]
  14. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Gschwind, A., Prenzel, N., Ullrich, A. Cancer Res. (2002) [Pubmed]
  15. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Lee, Z., Swaby, R.F., Liang, Y., Yu, S., Liu, S., Lu, K.H., Bast, R.C., Mills, G.B., Fang, X. Cancer Res. (2006) [Pubmed]
  16. Inhibition by cAMP of Ras-dependent activation of Raf. Cook, S.J., McCormick, F. Science (1993) [Pubmed]
  17. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Amano, M., Chihara, K., Kimura, K., Fukata, Y., Nakamura, N., Matsuura, Y., Kaibuchi, K. Science (1997) [Pubmed]
  18. Lysophosphatidic acid signalling. Moolenaar, W.H. Curr. Opin. Cell Biol. (1995) [Pubmed]
  19. LPA: a novel lipid mediator with diverse biological actions. Moolenaar, W.H. Trends Cell Biol. (1994) [Pubmed]
  20. Modulation of intestinal epithelial wound healing in vitro and in vivo by lysophosphatidic acid. Sturm, A., Sudermann, T., Schulte, K.M., Goebell, H., Dignass, A.U. Gastroenterology (1999) [Pubmed]
  21. Identification of a putative target for Rho as the serine-threonine kinase protein kinase N. Amano, M., Mukai, H., Ono, Y., Chihara, K., Matsui, T., Hamajima, Y., Okawa, K., Iwamatsu, A., Kaibuchi, K. Science (1996) [Pubmed]
  22. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. Xu, Y., Shen, Z., Wiper, D.W., Wu, M., Morton, R.E., Elson, P., Kennedy, A.W., Belinson, J., Markman, M., Casey, G. JAMA (1998) [Pubmed]
  23. Lysophosphatidic acid induces neointima formation through PPARgamma activation. Zhang, C., Baker, D.L., Yasuda, S., Makarova, N., Balazs, L., Johnson, L.R., Marathe, G.K., McIntyre, T.M., Xu, Y., Prestwich, G.D., Byun, H.S., Bittman, R., Tigyi, G. J. Exp. Med. (2004) [Pubmed]
  24. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Dikic, I., Tokiwa, G., Lev, S., Courtneidge, S.A., Schlessinger, J. Nature (1996) [Pubmed]
  25. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Chun, J., Goetzl, E.J., Hla, T., Igarashi, Y., Lynch, K.R., Moolenaar, W., Pyne, S., Tigyi, G. Pharmacol. Rev. (2002) [Pubmed]
  26. G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. Lu, W.Y., Xiong, Z.G., Lei, S., Orser, B.A., Dudek, E., Browning, M.D., MacDonald, J.F. Nat. Neurosci. (1999) [Pubmed]
  27. Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. Chrzanowska-Wodnicka, M., Burridge, K. J. Cell Biol. (1996) [Pubmed]
  28. PI 3-kinase gamma and protein kinase C-zeta mediate RAS-independent activation of MAP kinase by a Gi protein-coupled receptor. Takeda, H., Matozaki, T., Takada, T., Noguchi, T., Yamao, T., Tsuda, M., Ochi, F., Fukunaga, K., Inagaki, K., Kasuga, M. EMBO J. (1999) [Pubmed]
  29. Signal characteristics of G protein-transactivated EGF receptor. Daub, H., Wallasch, C., Lankenau, A., Herrlich, A., Ullrich, A. EMBO J. (1997) [Pubmed]
  30. Par-3 mediates the inhibition of LIM kinase 2 to regulate cofilin phosphorylation and tight junction assembly. Chen, X., Macara, I.G. J. Cell Biol. (2006) [Pubmed]
  31. Modular construction of a signaling scaffold: MORG1 interacts with components of the ERK cascade and links ERK signaling to specific agonists. Vomastek, T., Schaeffer, H.J., Tarcsafalvi, A., Smolkin, M.E., Bissonette, E.A., Weber, M.J. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  32. MEK kinase 1 gene disruption alters cell migration and c-Jun NH2-terminal kinase regulation but does not cause a measurable defect in NF-kappa B activation. Yujiri, T., Ware, M., Widmann, C., Oyer, R., Russell, D., Chan, E., Zaitsu, Y., Clarke, P., Tyler, K., Oka, Y., Fanger, G.R., Henson, P., Johnson, G.L. Proc. Natl. Acad. Sci. U.S.A. (2000) [Pubmed]
  33. Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Contos, J.J., Ishii, I., Fukushima, N., Kingsbury, M.A., Ye, X., Kawamura, S., Brown, J.H., Chun, J. Mol. Cell. Biol. (2002) [Pubmed]
  34. Modulation of cell surface fibronectin assembly sites by lysophosphatidic acid. Zhang, Q., Checovich, W.J., Peters, D.M., Albrecht, R.M., Mosher, D.F. J. Cell Biol. (1994) [Pubmed]
  35. Molecular cloning of a high-affinity receptor for the growth factor-like lipid mediator lysophosphatidic acid from Xenopus oocytes. Guo, Z., Liliom, K., Fischer, D.J., Bathurst, I.C., Tomei, L.D., Kiefer, M.C., Tigyi, G. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  36. Phospholipase D activity is required for actin stress fiber formation in fibroblasts. Kam, Y., Exton, J.H. Mol. Cell. Biol. (2001) [Pubmed]
  37. Export of mitochondrially synthesized lysophosphatidic acid. Haldar, D., Lipfert, L. J. Biol. Chem. (1990) [Pubmed]
  38. Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins. Thomas, E.A., George, R.C., Danielson, P.E., Nelson, P.A., Warren, A.J., Lo, D., Sutcliffe, J.G. Mol. Psychiatry (2003) [Pubmed]
WikiGenes - Universities